1. Home
  2. OXBR vs NEUP Comparison

OXBR vs NEUP Comparison

Compare OXBR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxbridge Re Holdings Limited

OXBR

Oxbridge Re Holdings Limited

N/A

Current Price

$1.44

Market Cap

11.6M

Sector

Finance

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.53

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXBR
NEUP
Founded
2013
1996
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
10.3M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
OXBR
NEUP
Price
$1.44
$4.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$5.00
$21.00
AVG Volume (30 Days)
17.7K
135.2K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,423,000.00
$15,649,448.00
Revenue This Year
$497.99
N/A
Revenue Next Year
$42.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.12
$2.90
52 Week High
$5.81
$21.40

Technical Indicators

Market Signals
Indicator
OXBR
NEUP
Relative Strength Index (RSI) 50.97 40.65
Support Level $1.30 $4.10
Resistance Level $1.44 $4.57
Average True Range (ATR) 0.06 0.27
MACD 0.03 0.25
Stochastic Oscillator 80.58 61.43

Price Performance

Historical Comparison
OXBR
NEUP

About OXBR Oxbridge Re Holdings Limited

Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: